Raffaella Greco, MD, PhD, San Raffaele Hospital, Milan, Italy, discusses cytomegalovirus (CMV) immune monitoring following allogeneic hematopoietic stem cell transplantation (alloHSCT). In recent years, new innovative drugs such as letermovir and maribavir have been introduced to prevent CMV infection. Studies have shown that letermovir is effective in reducing the risk of CMV infection in the first three months following transplantation, which underlines the importance of monitoring the immune response to CMV after this period. According to Dr Greco, understanding and measuring CMV-specific T-cell immunity can help us improve the clinical management of CMV infection by better stratifying patients into different risk groups, identifying patients at risk of CMV reactivation, and determining the duration of CMV prophylaxis. Dr Greco highlights the importance of harmonizing and standardizing the protocols and tools used for the immune monitoring of CMV infection after transplantation. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

свернуть